NCT02271360View on ClinicalTrials.gov

Calcium Dobesilate Versus Cabergoline for Prevention of Ovarian Hyperstimulation Syndrome

PHASE2/PHASE3CompletedINTERVENTIONAL
Enrollment

200

Participants

Timeline

Start Date

April 30, 2014

Primary Completion Date

December 31, 2015

Study Completion Date

December 31, 2015

Conditions
Infertility
Interventions
DRUG

Calcium Dobesilate

1 cap / 8 hs Calcium Dobesilate ( 500mg) will be given at day of HCG injection and for 21 days

DRUG

Cabergoline

1 tab/day Cabergoline( 0.5 mg) will be given at day of HCG injection and for 8 days

Trial Locations (1)

13518

Benha univesity hospital, Banhā

All Listed Sponsors
lead

Benha University

OTHER

NCT02271360 - Calcium Dobesilate Versus Cabergoline for Prevention of Ovarian Hyperstimulation Syndrome | Biotech Hunter | Biotech Hunter